文献速递糖尿病

踝臂指数对2型糖尿病微血管和大血管并发症的预后影响:里约热内卢2型糖尿病队列研究

Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
PubMed 文献 · Diabetologia · 2018-08-15

该研究在668例2型糖尿病患者中基线测量踝臂指数(ABI)并随访中位10年,评估ABI与微血管和大血管并发症及死亡的关系。结果显示ABI≤0.90与全因死亡、心血管死亡、MACE及周围神经病变风险增加相关,并改善心血管风险分层。

要点

  • ABI≤0.90与全因死亡风险增加2.1倍、心血管死亡风险增加2.7倍、MACE风险增加2.5倍相关。
  • ABI≤0.90与周围神经病变发生或恶化风险增加2.1倍相关,但与视网膜病变或肾脏结局无关。
  • ABI可改善经典危险因素之外的心血管风险判别,相对IDI从6.3%(全因死亡)到31%(心血管死亡)。

核心结论

  • 低ABI与心血管不良结局、死亡及周围神经病变发生或恶化的超额风险相关,并改善心血管风险分层。
  • ABI应在2型糖尿病患者中常规评估。

研究设计与样本

  • 里约热内卢2型糖尿病队列研究,基线测量668例2型糖尿病患者的ABI,随访中位10年。
  • 采用多变量Cox分析检验ABI与微血管及大血管并发症和全因死亡的关系,用C统计量和IDI指数评估风险分层改善。

主要发现

  • 随访期间168例发生心血管事件(140例MACE),191例死亡(92例心血管死亡);156例新发或视网膜病变恶化,194例达到肾脏复合结局(122例新发微量白蛋白尿,93例肾功能恶化),95例新发或周围神经病变恶化。
  • ABI作为连续或分类变量均与除非心血管死亡外的所有大血管和死亡结局显著相关。
  • 基线ABI≤0.90者全因死亡风险增加2.1倍(95%CI 1.3, 3.5;p=0.004),心血管死亡风险增加2.7倍(95%CI 1.4, 5.4;p=0.004),MACE风险增加2.5倍(95%CI 1.5, 4.4;p=0.001)。
  • ABI在经典危险因素之上改善风险判别,相对IDI从6.3%(全因死亡)到31%(心血管死亡)。
  • ABI≤0.90与周围神经病变发生或恶化相关(风险增加2.1倍[95%CI 1.1, 4.3];p=0.033),但与视网膜病变或肾脏结局无关。

临床怎么用

  • 在2型糖尿病患者中常规评估ABI,以识别心血管事件、死亡及周围神经病变发生或恶化风险较高的个体。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The prognostic importance of the ankle-brachial index (ABI) in individuals with diabetes is controversial. We aimed to evaluate the relationship between the ABI and the occurrence of micro- and macrovascular complications in individuals with type 2 diabetes. METHODS: The ABI was measured at baseline in 668 individuals with type 2 diabetes, and the individuals were followed-up for a median of 10 years. Multivariate Cox analysis was used to examine associations between the ABI and the occurrence of microvascular (retinopathy, microalbuminuria, renal function deterioration and peripheral neuropathy) and macrovascular (total cardiovascular events, major adverse cardiovascular events [MACE] and cardiovascular mortality) complications, and all-cause mortality. The improvement in risk stratification was assessed using the C statistic and the integrated discrimination improvement (IDI) index. RESULTS: During follow-up, 168 individuals had a cardiovascular event (140 MACE) and 191 individuals died (92 cardiovascular deaths); 156 individuals newly developed or experienced worsening diabetic retinopathy, 194 achieved the renal composite outcome (122 with newly developed microalbuminuria and 93 with deteriorating renal function) and 95 newly developed or experienced worsening peripheral neuropathy. The ABI, either analysed as a continuous or as a categorical variable, was significantly associated with all macrovascular and mortality outcomes, except for non-cardiovascular mortality. Individuals with a baseline ABI of ≤0.90 had a 2.1-fold increased risk of all-cause mortality (95% CI 1.3, 3.5; p = 0.004), a 2.7-fold excess risk of cardiovascular mortality (95% CI 1.4, 5.4; p = 0.004) and a 2.5-fold increased risk of MACE (95% CI 1.5, 4.4; p = 0.001). The ABI improved risk discrimination over classical risk factors, with relative IDIs ranging from 6.3% (for all-cause mortality) to 31% (for cardiovascular mortality). In addition, an ABI of ≤0.90 was associated with the development or worsening of peripheral neuropathy (2.1-fold increased risk [95% CI 1.1, 4.3]; p = 0.033), but not with retinopathy or renal outcomes. CONCLUSIONS/INTERPRETATION: A low ABI is associated with excess risk of adverse cardiovascular outcomes, mortality and peripheral neuropathy development or worsening, and improves cardiovascular risk stratification. The ABI should therefore be routinely evaluated in individuals with type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cardoso CRL, Melo JV, Salles GC, et al. Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia. 2018. PMID: 30112690. doi:10.1007/s00125-018-4709-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。